drugset / Trial / NCT01157169

Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions

NCT01157169

Phase 1 Completed 40 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The object of this study is to compare the rate and extent of absorption of an investigational formulation of buprenorphine 8 mg sublingual tablets manufactured by Barr Laboratories, Inc. to an equivalent oral dose of the commercially available reference product, Subutex® manufactured by Reckitt Benckiser, following and overnight fast of at least 10 hours.

Timeline

Start
2007-08
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Buprenorphine Other / unclassified 8 mg Other

Indications

No indication recorded.